healthcare AI platforms Patent
Portfolio.
Most "AI" companies patent model weights they cannot defend. Genzeon Platforms patents the methodology — how specialized agents coordinate to make defensible healthcare decisions. The result is a portfolio competitors cannot legally replicate by retraining a different model.
USPTO Customer #226167
More in preparation
Spans HIP One, PES One, CPS One, and future surfaces
Ten foundations. Each independently defensible.
The filed portfolio covers the methodology layer of healthcare AI — not a single product or model. Each patent protects an architectural primitive that recurs across HIP One, PES One, CPS One, and the agent marketplace, which is why the IP is platform-spanning by construction. Filings are summarized below at a high level; cross-references, claim language, and prior-art statements are available under NDA to qualified counterparties.
| Patent | What it covers |
|---|---|
| PA1 | Parallel Dual-Branch AI System for Healthcare Document Processing |
| PA2 | Atomic Criteria Decomposition |
| PA8-Core | Service-Oriented Agent Architecture |
| PA8-Deploy | Multi-Stakeholder Deployment Framework |
| PA16 | Ambient-Agent Integration |
| PA-CTX | Cross-Architecture Context Materialization |
| PA-LLM | CQL Execution Engine and LLM Routing |
| PA-SEC | Distributed Dual-Domain Threshold Cryptography |
| PA-RX | Pharmacy Benefit Prior Authorization Architecture |
| PA-AKPS | Auto-Affirmation Decision & Audit System |
More patents in preparation.
Additional patent applications are under active drafting and will be filed on a rolling cadence. To preserve filing position, specifics on subject matter and naming are not disclosed publicly — details are shared with qualified counterparties under NDA.
For customers and partners.
Patents only matter if they protect the right surface. Ours protect how the system thinks, not which model it uses today.
You're deploying technology competitors cannot legally replicate.
The architecture protected here — multi-agent orchestration, atomic criteria decomposition, cross-architecture context materialization, dual-domain cryptography — is the moat. Switching us to a different LLM does not infringe-around the portfolio.
The IP protects the methodology across every platform and every future product.
The portfolio is platform-spanning. The filed foundations apply equally to HIP One, PES One, CPS One, and any future Genzeon Platforms platform. Partners building on, integrating with, or distributing the platform inherit the moat by construction.
Inventors named on the Aether One™ portfolio.
Co-inventors on the provisional patent applications filed with the USPTO covering healthcare prior authorization automation, agentic substrate, and shared evidence infrastructure.
